Clik here to view.
ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease
Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with...
View ArticleClik here to view.
GSK immuno-oncology treatment achieves novel EU approval
The European Commission (EC) has approved the first frontline immuno-oncology treatment in the EU for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...
View ArticleClik here to view.
Novel heart failure drug could halt disease progression
The small molecule heart failure drug acoramidis has potential in slowing or stopping the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), according to study data published in the New...
View ArticleClik here to view.
Next-gen Moderna COVID-19 vaccine shows promise
Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data...
View ArticleClik here to view.
Novel LAI antipsychotic approved in EU
The first once-every-two-months long-acting injectable (LAI) antipsychotic approved by the European Commission (EC) is authorised as maintenance treatment for adults with schizophrenia in the EU. The...
View ArticleClik here to view.
Analysis of corticosteroid formulations in metered dose inhalers
Researchers have proposed a “promising” UV spectroscopic approach for quantifying both formoterol and beclomethasone formulations in pressurised metered dose inhalers. The team worked to develop an...
View ArticleClik here to view.
Utilising rapid UHPLC for tablet QC analysis
Researchers have developed and validated a rapid, sensitive, precise ultra high performance liquid chromatography (UHPLC) method for dual determination of the type 2 diabetes drugs, teneligliptin and...
View ArticleClik here to view.
AAV gene therapy demonstrates positive activity in Duchenne muscular dystrophy
New trial data for a gene therapy presented at the International Myology 2024 Congress has revealed “good” tolerability in Duchenne muscular dystrophy, when combined with transient immunological...
View ArticleClik here to view.
Benefits of 3D printing for personalised medicine formulation
A paper has reported the first time that 3D printing has facilitated two active pharmaceutical ingredients (APIs) to be combined in the same formulation. This method enables the number of...
View ArticleClik here to view.
Dissolution of capsule with cross-linking
What is dissolution? Dissolution tests determine the rate and extent of release of the drug substance from a drug product under specific conditions and specific times. Dissolution tests help to...
View ArticleClik here to view.
Non-chemotherapy lymphoma treatment may provide durable remission
A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. This was observed in...
View ArticleClik here to view.
Gilead small molecule demonstrates strong capability for HIV prevention
Gilead Sciences’ twice-yearly injectable HIV-1 capsid inhibitor enabled 100 percent efficacy for investigational use of HIV prevention in cisgender women. This is according to interim analysis topline...
View ArticleClik here to view.
Innovative small molecule shows promise in obesity
An innovative oral small molecule GLP-1 receptor agonist enabled patients to obtain an average weight loss of 4.9 percent to 6.8 percent (least squares means) from baseline by day 28, in a Phase I...
View ArticleClik here to view.
Pharma Horizons: Formulation
This report delves into the latest advances and developments impacting pharmaceutical drug formulators today. Inside, articles explore current vast expansion of the formulation including patient...
View ArticleClik here to view.
Innovative hypertension polypill study achieves “significant” outcomes
Three anti-hypertensive drugs combined in low doses into a single pill has been shown to be superior to standard care for lowering blood pressure in patients with uncontrolled hypertension. The oral...
View ArticleClik here to view.
Pharma Horizons: Biologics
This report delves into the latest developments impacting the pharmaceutical biologic drug sector today. Inside, articles explore current key topics including biosimilars, antibody drugs,...
View ArticleClik here to view.
Innovating allergy drug delivery with a needle-free alternative
In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. This decision was granted a couple of weeks...
View Article